Literature DB >> 7916060

Factors involved in entry of the human immunodeficiency virus type 1 into permissive cells: lack of evidence of a role for CD26.

I Lazaro1, D Naniche, N Signoret, A M Bernard, D Marguet, D Klatzmann, T Dragic, M Alizon, Q Sattentau.   

Abstract

It has been proposed recently that the cell surface peptidase CD26 acts in concert with CD4, the human immunodeficiency virus (HIV) primary receptor molecule, to mediate HIV entry into permissive cells. We have failed to detect significant levels of CD26 cell surface expression and enzymatic activity in a number of commonly propagated human CD4+ cell lines, although CD26 mRNA was present at very low levels, as detected by reverse transcription PCR. No relationship existed between the expression of CD26 and the ability of these cells to be infected with HIV or to fuse to form syncytia. We have tested two inhibitors of CD26 enzymatic activity and several anti-CD26 monoclonal antibodies and found that they inhibit neither HIV infection nor HIV-induced syncytium formation. NIH 3T3 cells stably transfected with the cDNAs for human CD4 and CD26 expressed these molecules at the cell surface and had CD26 enzymatic activity. Inoculation of the double transfectants with HIV did not result in virus entry above the background level, as verified by PCR amplification of viral DNA. We were unable to recover infectious virus from the HIV-inoculated NIH 3T3 double transfectants either by transfer of supernatants or by cocultivation with human CD4+ indicator cells. Moreover, the transfectants did not fuse with HIV-infected cells to form syncytia, nor were syncytia observed in HIV-inoculated cultures. These results are inconsistent with the CD26 molecule being a cofactor for entry of HIV in CD4+ cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7916060      PMCID: PMC237074     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

Review 1.  CD4: its structure, role in immune function and AIDS pathogenesis, and potential as a pharmacological target.

Authors:  R W Sweet; A Truneh; W A Hendrickson
Journal:  Curr Opin Biotechnol       Date:  1991-08       Impact factor: 9.740

2.  Response.

Authors:  C Callebaut; E Jacotot; B Krust; A G Hovanessian
Journal:  Science       Date:  1994-05-20       Impact factor: 47.728

3.  A chink in HIV's armour?

Authors:  P E Stephens; G Clements; G T Yarranton; J Moore
Journal:  Nature       Date:  1990-01-18       Impact factor: 49.962

4.  Differential ability of human immunodeficiency virus isolates to productively infect human cells.

Authors:  L A Evans; T M McHugh; D P Stites; J A Levy
Journal:  J Immunol       Date:  1987-05-15       Impact factor: 5.422

Review 5.  Human and simian immunodeficiency viruses: virus-receptor interactions.

Authors:  N Signoret; P Poignard; D Blanc; Q J Sattentau
Journal:  Trends Microbiol       Date:  1993-12       Impact factor: 17.079

6.  CD26 antigen and HIV fusion?

Authors:  C C Broder; O Nussbaum; W G Gutheil; W W Bachovchin; E A Berger
Journal:  Science       Date:  1994-05-20       Impact factor: 47.728

7.  Different requirements for membrane fusion mediated by the envelopes of human immunodeficiency virus types 1 and 2.

Authors:  T Dragic; M Alizon
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

8.  HLA-DR is involved in the HIV-1 binding site on cells expressing MHC class II antigens.

Authors:  D L Mann; E Read-Connole; L O Arthur; W G Robey; P Wernet; E M Schneider; W A Blattner; M Popovic
Journal:  J Immunol       Date:  1988-08-15       Impact factor: 5.422

9.  Involvement of a leukocyte adhesion receptor (LFA-1) in HIV-induced syncytium formation.

Authors:  J E Hildreth; R J Orentas
Journal:  Science       Date:  1989-06-02       Impact factor: 47.728

10.  Cleavage fragments of the retrovirus surface protein gp70 during virus entry.

Authors:  K B Andersen
Journal:  J Gen Virol       Date:  1987-08       Impact factor: 3.891

View more
  8 in total

1.  Successful immunomodulating in AIDS patients with ursodeoxycholic acid--a pilot study.

Authors:  D Kurktschiev; T Temelkova-Kurktschiev; K Horn; K Schentke
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

2.  Postbinding events mediated by human immunodeficiency virus type 1 are sensitive to modifications in the D4-transmembrane linker region of CD4.

Authors:  S Moir; J Perreault; L Poulin
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

3.  Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage.

Authors:  T Shioda; H Kato; Y Ohnishi; K Tashiro; M Ikegawa; E E Nakayama; H Hu; A Kato; Y Sakai; H Liu; T Honjo; A Nomoto; A Iwamoto; C Morimoto; Y Nagai
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

4.  Molecular mechanism for connective tissue destruction by dipeptidyl aminopeptidase IV produced by the periodontal pathogen Porphyromonas gingivalis.

Authors:  Yumi Kumagai; Hisao Yagishita; Ayako Yajima; Tatsuya Okamoto; Kiyoshi Konishi
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

5.  A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains.

Authors:  J F Berson; D Long; B J Doranz; J Rucker; F R Jirik; R W Doms
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

Review 6.  HIV: cell binding and entry.

Authors:  Craig B Wilen; John C Tilton; Robert W Doms
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

7.  Proteinase-resistant factors in human erythrocyte membranes mediate CD4-dependent fusion with cells expressing human immunodeficiency virus type 1 envelope glycoproteins.

Authors:  T Dragic; L Picard; M Alizon
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

Review 8.  Multiple roles for chemokines in the pathogenesis of SIV infection.

Authors:  Todd A Reinhart; Shulin Qin; Yongjun Sui
Journal:  Curr HIV Res       Date:  2009-01       Impact factor: 1.581

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.